PhaseBio Pharmaceuticals Inc. (PHAS) Reports Q4 Results, Provides Recent Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day streak of losses despite Middle East clashes
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
March 24, 2022 4:00 PM EDTAchieved key clinical milestones for bentracimab program, with positive results from both the completed Phase 2b trial and interim analysis of the ongoing REVERSE-IT global Phase 3 trial
Company remains on track to submit Biologics License Application (BLA) for bentracimab in mid-2022 and is preparing for expected commercialization in U.S.
PB6440, the companys aldosterone synthase inhibitor in development for resistant hypertension, on track for submission of an Investigational New Drug application (IND) in the second half of 2022
MALVERN, Pa. & SAN DIEGO--(BUSINESS... More
